BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kamat N, Ganesh Pai C, Surulivel Rajan M, Kamath A. Cost of Illness in Inflammatory Bowel Disease. Dig Dis Sci. 2017;62:2318-2326. [PMID: 28766243 DOI: 10.1007/s10620-017-4690-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Kamat N, Kedia S, Ghoshal UC, Nehra A, Makharia G, Sood A, Midha V, Gupta V, Choudhuri G, Ahuja V. Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study. Indian J Gastroenterol. 2019;38:44-54. [PMID: 30645725 DOI: 10.1007/s12664-018-0922-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
2 Kamp KJ, West P, Holmstrom A, Luo Z, Wyatt G, Given B. Systematic Review of Social Support on Psychological Symptoms and Self-Management Behaviors Among Adults With Inflammatory Bowel Disease. J Nurs Scholarsh 2019;51:380-9. [PMID: 31119856 DOI: 10.1111/jnu.12487] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
3 Rajbhandari R, Blakemore S, Gupta N, Adler AJ, Noble CA, Mannan S, Nikolli K, Yih A, Joshi S, Bukhman G. Crohn’s disease in low and lower-middle income countries: A scoping review. World J Gastroenterol 2020; 26(43): 6891-6908 [PMID: 33268969 DOI: 10.3748/wjg.v26.i43.6891] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Kamat N, Rajan Mallayasamy S, Sharma PSVN, Kamath A, Pai CG. Video assisted patient education improves compliance with follow up and depression scores in Inflammatory Bowel Diseases. Postgrad Med 2018;130:355-60. [PMID: 29460659 DOI: 10.1080/00325481.2018.1442978] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Banerjee R, Pal P, Mak JWY, Ng SC. Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia. Lancet Gastroenterol Hepatol 2020;5:1076-88. [PMID: 33181087 DOI: 10.1016/S2468-1253(20)30299-5] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
6 Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, Singer A, Lix LM, Hitchon CA, El-Gabalawy R, Katz A, Fisk JD, Bernstein CN; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease. Physical comorbidities increase the risk of psychiatric comorbidity in immune-mediated inflammatory disease. Gen Hosp Psychiatry 2018;51:71-8. [PMID: 29353127 DOI: 10.1016/j.genhosppsych.2018.01.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
7 Barahona MJ, Baratta V, Ollodart J, Mulligan D, Geibel JP. Design and implementation of novel nutraceuticals and derivatives for treating intestinal disorders. Future Med Chem 2019;11:847-55. [PMID: 30994367 DOI: 10.4155/fmc-2018-0313] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
8 Lawton J, Achit H, Pouillon L, Boschetti E, Demore B, Matton T, Tournier C, Prodel M, Peyrin-Biroulet L, Guillemin F. Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience. United European Gastroenterol J 2019;7:908-13. [PMID: 31428415 DOI: 10.1177/2050640619853448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
9 Dias CC, Santiago M, Correia L, Portela F, Ministro P, Lago P, Trindade E, Freitas A, Magro F; GEDII. Hospitalization trends of the Inflammatory Bowel Disease landscape: A nationwide overview of 16 years. Dig Liver Dis 2019;51:952-60. [PMID: 30826276 DOI: 10.1016/j.dld.2019.01.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
10 Santiago M, Magro F, Correia L, Portela F, Ministro P, Lago P, Trindade E, Dias CC. Inflammatory Bowel Disease Reoperation Rate Has Decreased Over Time If Corrected by Prevalence. Clin Transl Gastroenterol 2020;11:e00227. [PMID: 33094955 DOI: 10.14309/ctg.0000000000000227] [Reference Citation Analysis]
11 Kamat N, Rajan Mallayasamy S, Sharma P, Kamath A, Pai G. Effect of video-assisted patient education on compliance with therapy, quality of life, psychomorbidity, and cost of illness in irritable bowel syndrome. Postgrad Med 2019;131:60-7. [PMID: 30445893 DOI: 10.1080/00325481.2019.1549458] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Khalili H, Everhov ÅH, Halfvarson J, Ludvigsson JF, Askling J, Myrelid P, Söderling J, Olen O, Neovius M; SWIBREG Group. Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis: results from a nationwide study in Sweden. Aliment Pharmacol Ther 2020;52:655-68. [PMID: 32902894 DOI: 10.1111/apt.15889] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]